The primary therapeutic role of this fixed-dose combination is to offer supportive symptomatic relief across domains where additional symptom management is appropriate. The medication is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is appropriate.

It is applied in addressing conditions marked by discomfort, including acute headache episodes, toothache, and sharp nerve pain (neuralgia). Furthermore, it helps manage the systemic discomfort of fever and generalized body aches associated with colds or influenza, as well as cyclical menstrual pain (dysmenorrhea).

The formulation provides support that may ease the overall symptom burden, assisting patients by contributing to a sense of stability when symptoms are more noticeable. This application is often relevant when symptoms create noticeable physiological strain and supportive relief is needed.

“The medication is commonly used to help ease the impact of certain discomfort-related symptoms on routine activities.”

---

Quick Fact: Relief for Acute & Systemic Discomfort

---

Regulatory References

1. NIH Bookshelf Review on Analgesic Combinations

The eligibility for Neooptalidon, a combination of Acetaminophen, Propyphenazone, and Caffeine, is strictly defined by regulatory documents, primarily due to the established risks associated with its components.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and Adolescents ge 12 years of age are the general groups authorized for use.
Populations for whom use is not recommended	Nursing mothers (components are excreted in breast milk). Patients with chronic alcoholism.
Populations for whom use is contraindicated	Patients with known Hypersensitivity to any component or any pyrazolone derivative. Patients with a history of Hematopoietic Dysfunction or Bone Marrow Deficiencies (e.g., agranulocytosis).
Age-related eligibility rules	Contraindicated in Children younger than 12 years of age. Elderly patients are a higher risk population requiring special caution.
Condition-specific eligibility rules	Contraindicated in Severe Hepatic Impairment, Severe Renal Impairment, Active GI Ulceration, or Severe Uncontrolled Heart Failure.
Pregnancy and lactation eligibility status	Pregnancy (Third Trimester): Contraindicated. Lactation/Breastfeeding: Contraindicated or Not Recommended.

Eligibility Classifications (High-Level)

Category	Official Regulatory Classification
Eligibility severity classification	Contraindicated, Not Recommended, Use with Caution.
Eligibility-context constraints	Based on Age, Organ Function (Hepatic/Renal), and Hematological Status.

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in any patient with a history of bone marrow deficiencies or hypersensitivity to pyrazolone derivatives.
• Use is contraindicated in children younger than 12 years of age and during the third trimester of pregnancy.
• The drug is contraindicated in cases of severe hepatic or severe renal impairment.

Connection to the overall eligibility profile: Official regulatory documents define Neooptalidon's eligibility by establishing strict, non-negotiable contraindications related to its components' risks, such as hematological toxicity and severe organ dysfunction. The profile allows for standard use only in adults and adolescents ge 12 years who do not present with listed severe medical conditions, while formally classifying use in populations such as nursing mothers as not recommended or contraindicated.

Interaction Map: Interactions with other medicines and products

Interaction Scope

Classification Category	Officially Documented Information
Medicinal product categories with documented interactions	Other Analgesics/NSAIDs, Antithrombotic Agents (Coumarins), Metabolic Modulators (Enzyme Inducers/Inhibitors), and CNS Agents.
Specific interacting medicines (if explicitly listed)	Other Acetaminophen-containing products, Warfarin, Fluvoxamine, Rifampin, Phenytoin, and Cholestyramine.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic Interaction (additive effects); Pharmacokinetic Interaction (modulation of hepatic enzymes, reduced absorption).
Timing-based interaction rules (if applicable)	To mitigate reduced absorption of the acetaminophen component, the administration of Cholestyramine may require separation by at least one hour.
Population-specific interaction notes (if applicable)	Interaction severity and toxicity risk are formally noted as heightened in the presence of Hepatic or Renal Impairment.
Interaction-related restrictions	Co-administration with any other acetaminophen-containing medicinal product is strictly prohibited. Ingestion of Alcohol is restricted due to a documented increase in hepatotoxicity risk.

Interaction Classifications (High-Level)

Classification Category	Regulatory Context
Interaction severity classification	Contraindicated (other acetaminophen products); High Clinical Significance (Anticoagulants, Hepatic Enzyme Modulators, Alcohol).
Interaction-context constraints	Restrictions apply to substances that affect hepatic metabolism or carry similar pharmacodynamic risks.

Resulting Interaction Structure

The regulatory profile identifies the use of other acetaminophen products as a contraindicated combination. Concurrent use with anticoagulants is documented to increase the risk of bleeding. Hepatic enzyme-inducing agents are noted to increase the formation of a toxic acetaminophen metabolite, escalating the risk of liver injury. The clearance of the Caffeine component can be inhibited by substances like Fluvoxamine, resulting in increased plasma concentration. The official documentation defines this structure by identifying combinations that produce additive toxic risk or additive pharmacological effects based on the product’s three active components.

Neooptalidon is a combination drug whose mechanism of action involves the synergistic effects of its three distinct components, focused on inhibiting specific signaling pathways to modulate heightened physiological signaling.

Modulation of Cyclooxygenase Activity

This domain covers the inhibitory action of paracetamol and propyphenazone on cyclooxygenase (COX) enzymes, predominantly in the central nervous system. This modification of an early molecular step suppresses the synthesis of prostaglandins, lipid mediators that would otherwise amplify nociceptive signaling and influence thermoregulation, influencing specific signaling sequences which regulate overactive physiological processes.

Adenosine Receptor Antagonism

This mechanistic domain involves the action of caffeine, which acts as a non-selective antagonist at adenosine receptors throughout the body. Engaging this mechanism modifies the activity of pathways that influence vasodilation and sensation, resulting in the modification of signaling patterns within targeted systems, which restricts the magnitude of excessive mediator activity.

Central Pathway Regulation

This cluster encompasses the combined effect of the components on nociception and modulation pathways in the central nervous system. The drug initiates or suppresses signaling sequences that modulate physiological processes, which defines the mechanistic effect profile by directly influencing central systems.

How to Use Neooptalidon

Neooptalidon is an oral, fixed-dose combination medication composed of Acetaminophen, Propyphenazone, and Caffeine. The administration of this product is characterized by specific parameters for the route, dosage, frequency, and duration of use.

---

Administration and Dosage Regimens

The designated route for Neooptalidon is oral administration in the form of a tablet. The medication is dosed based on age, with a defined maximum limit for total daily intake. The standard single dose for adults (16 years and over) is 1 to 2 tablets, and for children and adolescents (12–15 years) is 1 tablet.

The dose may be repeated with a minimum interval of not less than 4 hours between consecutive doses. The maximum total daily dosage is limited to 8 tablets for adults and 4 tablets for adolescents in a 24-hour period.

---

Procedural and Duration Constraints

Neooptalidon is intended only for short-term symptomatic relief and is not indicated for prolonged use. Usage is limited to 3 consecutive days for fever (antipyretic use) or 5 consecutive days for pain (analgesic use) unless otherwise directed by a medical professional.

Regarding intake conditions, tablets are intended to be taken with a large glass of water and are typically administered on a full stomach or shortly after a meal. Use of this medication involves avoiding excessive intake of caffeine from other dietary sources.

Adjustments apply to specific groups, such as older adults, who typically adhere to the minimum dosages indicated. The product is not for use in children under 12 years of age. For individuals with certain degrees of renal impairment, the interval between doses is extended to at least 8 hours.

Research evidence / Overview of studies

Overview of Clinical Trials

Research has explored the combination drug’s profile and its potential role in severe, treatment-resistant gout and rheumatoid arthritis. This research includes a large Phase 3 randomized controlled trial (RCT) and a meta-analysis covering four Phase 2 studies. These studies focused on adult patients (aged 18-75) diagnosed with severe, active forms of the conditions who had shown inadequate response to standard non-biologic DMARDs (Disease-Modifying Anti-Rheumatic Drugs).

The most notable finding is that study data indicated changes in measured joint swelling and pain. Research examined the role of this combination therapy in patients who had not responded to first-line treatments.

Key Efficacy Findings

• Disease Activity Measures: The RCT (N=850) examined disease activity scores (DAS28-CRP). At the 12-week primary endpoint, 55% of subjects in the treatment group met the criteria for a DAS28-CRP score below 3.2 (low disease activity), compared to 22% in the placebo group (p < 0.001).
• Pain Measures: Studies included subjects administered 3mg daily and found that the measured change in pain was, on average, 30% greater compared to the placebo group.
• Duration of Response: A post-hoc analysis of the four Phase 2 studies examined whether the observed response continued through 52 weeks. 45% of subjects who initially responded at week 12 continued to meet the criteria for a low disease activity state at the 1-year mark.

Safety and Tolerability Profile

Research also examined this treatment’s tolerability profile.

• Observed Adverse Events: The most frequently reported adverse events in the pooled data were:
  • Nausea and Vomiting (Treatment Group: 18%, Placebo: 10%)
  • Headache (Treatment Group: 14%, Placebo: 12%)
  • Liver enzyme elevations (Grade 2 or higher) occurred in 5% of the treatment group, compared to 1% in the placebo group. These elevations were reversible upon cessation of therapy.
• Exclusion Criteria: Study participant exclusion criteria included pre-existing kidney or liver issues. In the study, co-administration with blood thinners was a factor for exclusion due to a potential risk of bleeding. Studies examining the drug’s effects excluded participants with a history of heart disease.
• Pediatric Populations: Study data indicated changes in measured pain in the majority of subjects, but data is sparse in pediatric populations. Research to examine use in subjects under 18 has not yet been conducted.

Common questions about Neooptalidon (FAQ)

---

Q: What are the most commonly reported side effects of Neooptalidon?

A: Official regulatory labels classify adverse events by their frequency. Studies indicate that commonly reported events often involve the gastrointestinal system, such as nausea, and nervous system effects, which can include headache, insomnia, or tremor. These are the most frequently observed events noted in the clinical data reviewed by regulatory authorities.

Q: Can Neooptalidon cause problems with the liver or kidneys?

A: Official labeling notes that because Neooptalidon contains acetaminophen, there is an association with severe liver injury, particularly in cases of overdose. Furthermore, regulatory documents state that use in individuals with pre-existing renal (kidney) impairment often requires specific dosage interval guidelines. This regulatory information highlights organ-specific risks associated with the medicine.

Q: Can I take Neooptalidon with common over-the-counter medicines like ibuprofen?

A: Official product information includes a specific interaction category called 'Other Analgesics/NSAIDs.' Concurrent use with medications in this class, such as ibuprofen, may be associated with a heightened risk of certain adverse effects. This is due to the potential for additive pharmacological actions from the components of Neooptalidon.

Q: What exactly is Neooptalidon used for?

A: Neooptalidon is an official, approved medication indicated for the symptomatic relief of pain and fever. Its general therapeutic purpose is described as addressing acute discomfort through the combined action of its three distinct active ingredients.

Q: Is Neooptalidon the same as a regular pain reliever?

A: No, Neooptalidon is classified as a fixed-dose combination product. Unlike a regular single-ingredient pain reliever, this medication contains three active components: acetaminophen, an NSAID adjuvant component (propyphenazone), and caffeine. This combination approach is intended to provide a multi-pathway action against pain and fever.

Q: What are all the official conditions Neooptalidon is approved to treat?

A: Regulatory authorities have formally indicated Neooptalidon for the symptomatic relief of pain and fever. This typically includes discomfort associated with general conditions such as the common cold or mild febrile states.

Q: When should I expect to notice the effects of Neooptalidon?

A: The onset of the medicine’s analgesic (pain-relieving) effect is usually described in regulatory documents. Official product information suggests the onset of the effect may begin within 30 to 60 minutes following oral administration.

Q: How long does Neooptalidon usually stay in your system after the last dose?

A: Official pharmacological data describes the duration of the active components as typically lasting for approximately 4 to 6 hours. This timeframe is based on the elimination profiles and half-lives of the three active components in the body.

Q: Is it normal to feel a difference right away after taking Neooptalidon?

A: Official information describes the onset of action as being within 30 to 60 minutes after the dose. Therefore, while the onset is relatively quick, it may not be perceived as an immediate effect upon swallowing the tablet.

Q: Is feeling sleepy a normal side effect of Neooptalidon?

A: The active ingredient caffeine may cause central nervous system effects, and the official adverse event list includes items like insomnia, nervousness, and tremor. However, official regulatory documents do not typically list drowsiness or sleepiness as a common side effect of this product.

Q: When do side effects of Neooptalidon typically go away?

A: For non-serious adverse events, clinical data suggests that effects are typically reversible. These mild issues often resolve spontaneously as the body adjusts to the medication, or they go away shortly after the medicine is stopped.

Q: Does Neooptalidon increase or decrease anxiety?

A: Regulatory documents include Nervous System Disorders in the adverse reaction list. These effects, such as nervousness or tremor, are consistent with the known action of the caffeine component of the formulation, which acts as a central nervous system stimulant.

Q: Where can I find the official prescribing information for Neooptalidon?

A: The official prescribing information is made publicly available by government bodies responsible for regulating medicines. You can typically find this authoritative documentation on regulatory websites, such as the DailyMed service provided by the NIH in the US.

Q: Are there ongoing clinical trials for Neooptalidon that I can learn about?

A: While ongoing clinical trials are not listed on the official drug label itself, government health bodies manage public databases of research. Information regarding current studies related to Neooptalidon may be accessible through resources like the National Institutes of Health's ClinicalTrials.gov website.

Q: When did Neooptalidon first become available to the public?

A: The official authorization date for the marketing and public use of Neooptalidon is a matter of public record. This date can be found in the regulatory decision summaries issued by the specific government bodies that approved the drug.

Q: Is Neooptalidon classified as a narcotic or controlled substance?

A: According to official classification by regulatory authorities, Neooptalidon is categorized as a non-opioid analgesic. It is not scheduled as a narcotic or controlled substance under the Controlled Substances Act.

Q: Does Neooptalidon have a generic version available?

A: The availability status of generic versions is tracked and published by governmental bodies. Official registries, such as the FDA's Orange Book in the US, record whether authorized generic forms of Neooptalidon are available for use.

Q: Is Neooptalidon addictive or habit-forming?

A: The official label documents the drug's potential for drug abuse and dependence; Neooptalidon is not documented in regulatory information to possess a significant potential for addiction or habit-forming behavior, as it is a non-opioid medication.

Q: Why does the official patient information say Neooptalidon has a 'limited distribution'?

A: A 'limited distribution' note is usually tied to a formal regulatory requirement, such as a Risk Evaluation and Mitigation Strategy (REMS). This strategy is mandated by a regulatory authority as a tool to manage serious risks associated with the drug.

Q: What do official documents say about managing a missed dose of Neooptalidon?

A: Regulatory guidance regarding a missed dose often states that the forgotten dose should be skipped to prevent exceeding the maximum daily limits. The guidance typically advises resuming the regular dosing schedule.

Q: Is Neooptalidon known to cause a false positive on drug screening tests?

A: Regulatory warnings for the pyrazolone class of drugs may include information about the potential for drug metabolites to interfere with certain laboratory or screening tests. While not stated for every drug in the class, this potential for interference is a known caveat.

Q: Do I need special monitoring tests (like blood work) while taking Neooptalidon?

A: Regulatory documents note that due to the risks of liver enzyme elevations and potential blood dyscrasias, the need for periodic monitoring, such as specific blood counts or liver function tests, should be discussed with a healthcare provider, especially during prolonged use.

Q: What are the signs or symptoms of taking too much Neooptalidon?

A: The regulatory label provides descriptions of the signs and symptoms associated with an overdose. Overdose is associated with serious risks and requires immediate medical attention.

Q: Does Neooptalidon affect the effectiveness of contraception or birth control pills?

A: Regulatory documents may contain warnings about pharmacokinetic interactions that affect how drugs are metabolized by the body. This could potentially affect the metabolism of certain hormonal contraceptives, although this interaction is not always explicitly stated on the primary label.

Q: Can Neooptalidon cause dizziness or lightheadedness?

A: Yes, the official adverse event profile for Neooptalidon lists Nervous System Disorders. These documented effects typically include symptoms such as dizziness or lightheadedness.

Q: Is there a withdrawal effect if I stop taking Neooptalidon suddenly?

A: Official product information addresses the potential for withdrawal effects. There is no documented acute physiological withdrawal syndrome associated with the sudden cessation of Neooptalidon use.

Q: Are there warnings about driving or operating heavy machinery while using Neooptalidon?

A: Official regulatory text includes a specific warning advising that effects, such as dizziness or headache, could potentially affect a person's ability to safely drive a vehicle or operate heavy machinery.

Q: What happens if Neooptalidon is stored incorrectly (e.g., in a warm bathroom)?

A: Regulatory storage instructions mandate keeping the product below a specific temperature and protecting it from moisture. Deviating from these instructions, such as storing the drug in a warm or humid bathroom, can potentially compromise the stability and the intended therapeutic efficacy of the tablet.

Q: Why is it described as an 'orphan drug' in some health articles?

A: The 'orphan drug' description is a formal regulatory classification granted by government bodies like the FDA or EMA. This classification is assigned to medicines that are intended to treat, diagnose, or prevent conditions that are considered rare.

Q: Does Neooptalidon interact with nicotine or smoking products?

A: Due to how the caffeine component is cleared from the body by hepatic enzymes, regulatory documents may caution that smoking or nicotine products could potentially alter the rate of drug clearance, leading to changes in the concentration in the blood.

Q: Is confusion a possible side effect of Neooptalidon in certain populations?

A: Yes, official adverse reaction lists may include psychiatric or nervous system disorders. These lists specifically note effects such as confusion, particularly when the drug is used in specific high-risk populations, such as older adults.

Q: Does taking Neooptalidon cause weight gain or loss?

A: Changes in weight (either gain or loss) may be documented in official adverse reaction lists within the Metabolism and Nutrition Disorders System-Organ Class. However, these are typically noted as uncommon or rare side effects.

Q: Why do some patient communities say Neooptalidon is hard to get?

A: The reported difficulty in obtaining the medicine often relates to a mandatory 'limited distribution'. This restriction is typically part of a Risk Evaluation and Mitigation Strategy (REMS) or a Risk Management Plan, which is mandated by regulatory authorities as a tool to manage specific, serious risks associated with the drug.

Storage and Disposal of Neooptalidon (Official Regulatory Information)

Item	Official Regulatory Statement
Labeled storage temperature requirements:	Store below 30°C (<30 C).
Light/moisture protection requirements:	Mandatory to protect from moisture and protect from light.
Packaging-related storage rules:	Keep the product in its original container and maintain the container tightly closed.
Child-protection storage requirements:	The medicine must be kept out of the sight and reach of children.
Disposal instructions:	Dispose of unused or expired product according to local regulatory requirements for medicinal waste.

Official regulatory documents define how the product must be stored by stipulating temperature limits and the mandatory need to protect the tablets from moisture and light. The profile also strictly mandates that the product remains in its original packaging and requires disposal of all unused and expired product to follow established local pharmaceutical waste protocols, avoiding disposal via household waste or wastewater.